A detailed history of Barclays PLC transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Barclays PLC holds 16,128 shares of KRON stock, worth $13,870. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,128
Previous 16,128 -0.0%
Holding current value
$13,870
Previous $16,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 03, 2023

SELL
$1.24 - $1.92 $29,213 - $45,233
-23,559 Reduced 59.36%
16,128 $28,000
Q1 2023

May 04, 2023

BUY
$1.34 - $2.62 $16,929 - $33,101
12,634 Added 46.7%
39,687 $58,000
Q4 2022

Feb 13, 2023

BUY
$1.44 - $3.44 $13,248 - $31,648
9,200 Added 51.53%
27,053 $44,000
Q3 2022

Nov 03, 2022

SELL
$3.35 - $5.55 $6,780 - $11,233
-2,024 Reduced 10.18%
17,853 $60,000
Q2 2022

Aug 12, 2022

BUY
$3.12 - $7.52 $29,980 - $72,259
9,609 Added 93.58%
19,877 $72,000
Q1 2022

May 16, 2022

BUY
$6.26 - $14.42 $64,277 - $148,064
10,268 New
10,268 $77,000

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $48.8M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.